Rituximab (genetical recombination)

BIOLOGICAL2 trials

Sponsors

Nagoya University, Shoichi Maruyama MD PhD

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Glomerulonephritis, MembranousNephrotic Syndrome，Idiopathic

Phase 2

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

CompletedNCT03864185

Nagoya UniversityChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Start: 2019-03-28End: 2021-05-27Updated: 2021-08-20

Phase 3

Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome

Active, not recruitingNCT05914155

Shoichi Maruyama MD PhDGlomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic

Start: 2023-06-24End: 2028-06-30Target: 88Updated: 2026-08-12

Related Papers

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol

PLoS ONE2025-03-18

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

JMIR Research Protocols2020-04-0132 citations